Chongfan Technology
News
05
2024
-
08
Nat Commun | Yu Jiayi Team Discovers Potential New Applications of circRNA
Author:
Delivering synthetic protein-coding RNA to bypass the DNA stage to achieve ectopic protein function is a new therapeutic strategy. Covalently linking linear RNAs from start to finish may be a state-of-the-art strategy for extending function.
On August 4, 2024, Yu Jiayi, the National Institutes of Health of Taiwan, China, as the corresponding author, was inNature Communications Published online entitled“A cis-acting ligase ribozyme generates circular RNA in vitro for ectopic protein functioning”The research paper,The studyThe cis-ligase ribozyme (RzL) was recruited to generate circular RNA (circRNA) in vitro for ectopic protein expression.
The circularization of the RNA was confirmed by masking the 5 'phosphate group, resisting cleavage by the exonuclease RNase R, failing to add further tails, and sequencing the RT-PCR product of the junction region. Interestingly, an internal ribosome entry site (IRES) enables circRNA to translate, but two IRES in cis (but not trans) hinder translation. circRNA with high translation ability are endowed with antiviral function.With a specific guide RNA, the circRNA expressing the ribonuclease Cas13 shows good potential against the corresponding RNA virus, further expanding the functionality of circRNA in its growing list of applications.
The successful introduction of messenger RNA (mRNA) encoding SARS-CoV-2 spike proteins as a novel vaccine strategy has certainly stimulated the potential of RNA research in molecular therapeutics.In theory, the longer the half-life of the mRNA in the cell, the longer the functional duration of the mRNA and the lower the amount of mRNA that needs to be delivered. Most mRNAs have 5 '-cap and 3' polyA, which are connected with various cellular proteins to form a ring structure, effectively express proteins and avoid exonuclease digestion.In order to improve the translation efficiency and longevity of exogenous mRNA in cells, the covalent cyclization of single-stranded mRNA into circular RNA (circRNA) has become a new option.
An internal ribosome entry site (IRES)-driven protein translation cassette can accommodate circRNA translation initiation in the absence of a 5 '-cap.circRNA can be generated in vitro by lengthy chemical or enzymatic RNA ligation. Alternatively, drawing on the RNA self-splicing mechanism of group I introns, permuted intron-exon (PIE) splicing has become a popular strategy for circular RNA formation, with partial exons and corresponding complementary sequences fused on both sides of the intron. When the RNA elements of introns, splice sites, and exons are properly aligned, RNA acts as an enzyme, the so-called ribozyme, catalyzing the splicing event, forming circular RNA through RNA breakdown and rejoining. RNA splicing-based circularization strategies can tolerate large amounts of linear RNA in vitro and in vivo, but consume RNA sequence length quotas due to splicing waste.Although GTP and Mg2 Under the special conditions of accelerated PIE splicing in vitro, the small by-product RNA after splicing of course requires additional removal procedures to avoid the uncertainty of possible side effects.

An external IRES of cis rather than trans hinders the translation of circRNA
The covalent circularization of single-stranded RNA by a cis-acting ligase ribozyme (RzL) selected in a systematic screening study minimized the RNA sequence required for RzL to act in trans.The RzL strategy recruits a RzL carrying 5 '-triphosphate (ppp) during in vitro transcription (IVT), directly and autonomously added to the corresponding substrate sequence at the 3' end. Unlike splicing methods that obtain GTP to promote circRNA formation, the RzL strategy is highly dependent on enzyme-substrate RNA pairing to produce circRNA without by-product RNA. Although the biophysical properties of protein-coding circRNA are not well understood,However, the study of the protein translation characteristics of the two-chain circRNA expressing the two proteins provides important information for circRNA experiments on the function and application of foreign proteins.
Chongqing Chongfan Technology Co., Ltd. Optical platform film thickness meter OCT optical coherence tomography LabVIEW control
LATEST NEWS
Thank you for visiting the official website of Chongfan Technology. If you have cooperation intentions or suggestions, please contact us through the following methods, and we will reply as soon as possible, thank you!
Address: Room 403, Building 6, Phase III of R&D, No. 36 Xiyong Avenue, High tech Zone, Chongqing, China.
Telephone: +86-13658337211
E-mail: Sales@cfkeji.net
Website: www.cfkeji.net
Mobile Version